Raia Drogasil S.A.
RADLY | OTC
$2.88
+$0.14 (+5.11%)
Nov 2, 2026, 11:01 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 44.25B | 38.86B | 33.97B | 29.07B | 24.13B | 20.07B |
Cost of Revenue | 33.3B | 27.31B | 23.77B | 20.26B | 18.21B | 14.18B |
Gross Profit | 10.95B | 11.55B | 10.21B | 8.81B | 7.21B | 5.89B |
Operating Income | 2.64B | 2.37B | 2.08B | 1.84B | 1.37B | 894.72M |
Interest Income | 19.4M | 36.07M | 45.91M | -114.69M | -72.72M | -7.93M |
Pretax Income | 1.45B | 1.42B | 1.22B | 1.19B | 987.26M | 616.37M |
Net Income | 1.3B | 1.2B | 1.05B | 996.11M | 751.93M | 484.44M |
Selling & General & Admin | 10.29B | 9.19B | 8.19B | 7.06B | 5.88B | 4.94B |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -1.98B | -12.13M | -65.93M | -85.7M | -46.34M | 40.23M |
Operating Expenses | 8.31B | 9.18B | 8.13B | 6.98B | 4.51B | 4.94B |
Interest Expense | 1.07B | 790.95M | 737.79M | 559.22M | 316M | 297.01M |
Selling & Marketing Expenses | 8.72B | 7.63B | 6.69B | 5.81B | 4.97B | 4.26B |
Cost & Expenses | 41.61B | 36.5B | 31.89B | 27.23B | 22.8B | 19.11B |
Income Tax Expense | 147.81M | 206.51M | 129.55M | 178.24M | 223.13M | 120.84M |
Shares Outstanding (Basic) | 1.65B | 1.65B | 1.63B | 1.65B | 1.72B | 1.72B |
Shares Outstanding (Diluted) | 1.66B | 1.65B | 1.7B | 1.65B | 1.72B | 1.72B |
EPS (Basic) | 0.79 | 0.73 | 0.65 | 0.60 | 0.44 | 0.28 |
EPS (Diluted) | 0.78 | 0.73 | 0.62 | 0.60 | 0.44 | 0.28 |
EBITDA | 4.65B | 3.14B | 2.75B | 2.45B | 2.6B | 2.08B |
EBIT | 2.64B | 2.23B | 1.95B | 1.75B | 1.3B | 899.74M |
Depreciation & Amortization | 2.01B | 911.97M | 797.69M | 700.17M | 1.29B | 1.18B |
Add to Watchlist
Select watchlists to add or remove RADLY